Chemistry:Elimusertib
From HandWiki
Elimusertib (Bay 1895344) is an experimental anticancer drug which acts as an inhibitor of ataxia telangiectasia and Rad3 related protein. This is involved in DNA repair following damage, and so inhibiting this protein causes cancer cells to become more vulnerable to other chemotherapy drugs. Elimusertib is in early stage clinical trials against advanced solid tumors.[1][2][3][4]
References
- ↑ "Damage Incorporated: Discovery of the Potent, Highly Selective, Orally Available ATR Inhibitor BAY 1895344 with Favorable Pharmacokinetic Properties and Promising Efficacy in Monotherapy and in Combination Treatments in Preclinical Tumor Models". Journal of Medicinal Chemistry 63 (13): 7293–7325. July 2020. doi:10.1021/acs.jmedchem.0c00369. PMID 32502336.
- ↑ "The Novel ATR Inhibitor BAY 1895344 Is Efficacious as Monotherapy and Combined with DNA Damage-Inducing or Repair-Compromising Therapies in Preclinical Cancer Models". Molecular Cancer Therapeutics 19 (1): 26–38. January 2020. doi:10.1158/1535-7163.MCT-19-0019. PMID 31582533.
- ↑ "First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors". Cancer Discovery 11 (1): 80–91. January 2021. doi:10.1158/2159-8290.CD-20-0868. PMID 32988960.
- ↑ "Preclinical Evaluation of the ATR Inhibitor BAY 1895344 as a Radiosensitizer for Head and Neck Squamous Cell Carcinoma". International Journal of Radiation Oncology, Biology, Physics 118 (5): 1315–1327. April 2024. doi:10.1016/j.ijrobp.2023.12.012. PMID 38104870.
 |  |
